Alcohol Use Disorder Risk and Your Genetics

Reviewed by the ExomeDNA Science Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

Alcohol use disorder (AUD) is a chronic condition defined by the development of physical dependence on alcohol — including tolerance and withdrawal symptoms when drinking stops — and it affects an estimated 29 million adults in the United States. Genetic variation across at least seven well-characterized genes shapes an individual's metabolic processing of alcohol, dopamine reward signaling, liver glucose regulation, zinc transport, FGF21-mediated craving control, and cochlear vulnerability to alcohol-related damage. Below: what those genes do, what the research shows, and how to act on your ExomeDNA result.

What is alcohol use disorder?

Alcohol use disorder sits at the severe end of a spectrum of alcohol-related problems. What separates AUD from hazardous or harmful drinking is physical dependence: the body adapts to the chronic presence of alcohol at the neurochemical level, so that removing it triggers a physiological withdrawal syndrome. Withdrawal symptoms range from anxiety and insomnia at the mild end to tremors, hallucinations, seizures, and — in the most severe presentation — delirium tremens, a potentially life-threatening state requiring emergency medical management.

Tolerance is the other hallmark. Over time, the same quantity of alcohol produces a diminishing subjective effect, driving escalating consumption to achieve the same relief or pleasure. This escalation is partly mediated by neuroadaptation in dopamine, GABA, and glutamate systems — changes that genetic variation influences from the outset.

AUD is a medical condition, not a character defect. Its heritability is estimated at 40–60%, placing it firmly in the range of conditions like type 2 diabetes and hypertension where genes contribute meaningfully alongside environment, social context, and behavior.

The genetics behind alcohol use disorder risk

Seven authorized genes are relevant to this ExomeDNA result. Each affects a different biological pathway.

ADH1B (alcohol dehydrogenase 1B) encodes the primary enzyme that converts ethanol to acetaldehyde in the liver. The rs1229984 variant dramatically speeds this conversion, causing a rapid acetaldehyde accumulation that produces flushing, nausea, and cardiovascular discomfort — a built-in aversive response that strongly discourages heavy drinking. Carriers of the protective allele have substantially lower rates of AUD. People without it face no such biological brake on alcohol metabolism.

DRD2 (dopamine D2 receptor) is the most mechanistically important gene for understanding why AUD is hard to stop once established. The dopamine D2 receptor governs the brain's ability to register pleasure and reward from natural activities — food, social connection, exercise, creative work. Chronic heavy alcohol use causes progressive D2 receptor downregulation: the brain produces fewer receptors as a compensatory response to the dopamine flooding driven by alcohol. The consequence is withdrawal dysphoria — a sustained inability to feel pleasure from anything other than alcohol during early abstinence. DRD2 variants determine baseline receptor density, which sets the starting point for this downregulation process and influences how quickly receptor numbers recover during sustained sobriety. Variants associated with lower baseline D2 density confer greater vulnerability to reward system collapse in AUD.

KLB (beta-Klotho) encodes the obligate co-receptor for fibroblast growth factor 21 (FGF21) signaling. FGF21 is a liver-derived hormone with a well-documented role in alcohol appetite regulation: it rises after alcohol exposure and signals the brain to reduce further consumption. This is a natural homeostatic brake. People with KLB variants that impair FGF21 co-receptor sensitivity have a diminished version of this brake. During withdrawal, when alcohol is removed and FGF21 levels shift, impaired KLB-mediated signaling may produce more intense craving because the liver's "stop drinking" signal was already operating below full strength. This pathway has become a target of early-stage pharmacological interest.

FTO (fat mass and obesity-associated gene) is best known for its role in energy homeostasis and body weight regulation, but its relevance in AUD is metabolic. Alcohol delivers approximately 7 kilocalories per gram — comparable to fat — with no micronutrient value. Heavy drinking therefore adds substantial caloric load on top of disrupted appetite regulation. FTO variants affecting energy sensing interact with alcohol's caloric contribution, influencing body weight trajectory and metabolic syndrome risk in people with significant AUD history.

GCKR (glucokinase regulatory protein) regulates glucose sensing in the liver. The liver is the primary site of alcohol metabolism, and chronic heavy drinking disrupts hepatic glucose regulation through multiple mechanisms including glycogen depletion and impaired gluconeogenesis. GCKR variants affecting how the liver senses and responds to glucose influence the severity of metabolic complications — including hypoglycemia, dyslipidemia, and non-alcoholic fatty liver progression — in people with AUD.

SLC39A8 (zinc transporter ZIP8) transports zinc across cell membranes, and this has a specific relevance in AUD that is often overlooked. Chronic heavy alcohol consumption causes progressive zinc depletion through multiple routes: reduced dietary intake, impaired intestinal absorption, and increased urinary zinc excretion. Zinc is a critical modulator of GABA-A receptor function — zinc ions normally bind to GABA-A receptors and inhibit their activity, fine-tuning the inhibitory tone of the central nervous system. When zinc is depleted, this inhibitory modulation is reduced, which may contribute to the excitatory imbalance underlying alcohol withdrawal seizures. SLC39A8 variants affecting zinc transport efficiency influence how quickly zinc depletion accumulates during heavy drinking and how readily zinc levels recover during abstinence.

TMPRSS5 (transmembrane serine protease 5) is expressed in the cochlea — specifically in the spiral ganglion neurons and hair cells of the inner ear — and is implicated in normal hearing function. Chronic alcohol use is an established cause of auditory system damage through metabolic and oxidative toxicity to cochlear tissue. The link between AUD and hearing loss, including high-frequency hearing decline and tinnitus, is documented but underrecognized as an AUD complication. TMPRSS5 variation is associated with audiometric traits in genome-wide data, suggesting that genetic differences in cochlear biology may influence individual vulnerability to this specific AUD-related complication.

What the research says

Research base: Robust.

The genetic architecture of alcohol use disorder and alcoholism-spectrum phenotypes has been studied in some of the largest genetic cohorts ever assembled.

The primary source supporting this ExomeDNA result is a 2024 study by Verma and colleagues (PMID 39024449) examining the genetic architecture of 2,068 traits across the VA Million Veteran Program — one of the largest and most ancestrally diverse biobank studies ever conducted. The scale of this work — over one million participants with linked electronic health records — provides substantially greater statistical power to detect genetic signals for AUD-related phenotypes than earlier, smaller studies, and the ancestral diversity improves the generalizability of findings beyond European-ancestry cohorts.

The biological mechanisms for several of the genes listed above — particularly ADH1B, DRD2, and KLB — have been validated across independent cohorts and multiple phenotypic approaches including both case-control designs and continuous alcohol consumption measures. The TMPRSS5 hearing connection represents a more recent and mechanistically emerging line of evidence, appropriately weighted as a plausible complication pathway rather than a primary dependence mechanism.

How alcohol use disorder affects you

The effects of AUD operate across biological, neurological, metabolic, and systemic domains simultaneously.

Neurologically, D2 receptor downregulation is among the most consequential changes. Brain imaging studies show that those with AUD have measurably reduced D2 receptor availability in the striatum compared to controls, and that this deficit persists for weeks to months into early recovery. During this window, the inability to experience normal reward from everyday activities — the withdrawal dysphoria described above — is a major driver of relapse. Recovery of D2 receptor density is gradual and is meaningfully supported by activities that engage the dopamine reward system through natural means.

Metabolically, the liver bears the primary burden of alcohol processing. Fatty liver disease, alcoholic hepatitis, and cirrhosis represent the progression of liver injury in sustained heavy drinking. GCKR and FTO variants interact with this metabolic load by influencing how the liver and adipose tissue manage the caloric and glucose disruption that alcohol imposes.

Nutritionally, zinc and B-vitamin depletion are well-documented in AUD. Zinc deficiency (influenced by SLC39A8 transport efficiency) impairs immune function, wound healing, and as noted above, GABA-A receptor modulation. Thiamine (vitamin B1) depletion leads to Wernicke's encephalopathy in severe cases — a medical emergency.

Audiologically, hearing loss and tinnitus are more prevalent in individuals with AUD than the general population, a complication frequently attributed to alcohol's cochlear toxicity. TMPRSS5 expression in spiral ganglion neurons positions this gene as a plausible modifier of individual cochlear vulnerability, though this remains an area of active investigation rather than a fully established clinical predictor.

Working with your alcohol use disorder result

Your ExomeDNA result reflects polygenic risk based on population-level genetic association data. This is not a clinical finding and does not predict whether AUD will occur. What it does provide is information about biological pathways that may be relevant to your risk profile. Use it in the context of your overall health history and in consultation with a clinician.

For alcohol use disorder generally, the research literature describes the following evidence-grounded approaches:

1. Medical supervision for any alcohol withdrawal. If you currently drink heavily and are considering stopping, do not stop abruptly without medical evaluation. Alcohol withdrawal seizures can be life-threatening. Seek medical assessment — supervised withdrawal (detoxification) with appropriate pharmacological support (typically benzodiazepines) is the evidence-based standard.

2. Evidence-based pharmacotherapy. Naltrexone, an opioid receptor antagonist, reduces alcohol craving and relapse rates in clinical trials by attenuating the dopamine reward signal that drives continued drinking. Acamprosate supports GABA/glutamate balance during early abstinence. Both are FDA-approved for AUD treatment and both are significantly underused.

3. Address zinc status during recovery. Zinc depletion is common in AUD history. A clinician can check serum zinc and recommend supplementation if indicated. Restoring zinc is particularly relevant given SLC39A8's role in zinc transport and the GABA-A modulating function of zinc in neurological recovery.

4. Schedule an audiological evaluation. For those with a significant history of heavy alcohol use, audiometry (a hearing test) is a reasonable preventive screen. Alcohol-related hearing loss is often high-frequency and progressive; early identification allows for monitoring and management.

5. Prioritize dopamine-restoring activities during recovery. Exercise, in particular, has documented effects on dopamine receptor density and neuroplasticity. Social engagement, creative work, and novelty-seeking activities that don't involve substance use all activate the dopamine reward system and support D2 receptor recovery over time. This is mechanistically grounded, not generic wellness advice.

6. Support liver and FGF21 function. Minimizing added sugars and fructose, maintaining a healthy body weight, and avoiding additional hepatotoxic substances support liver health and the FGF21 signaling axis that naturally helps regulate alcohol appetite via the KLB receptor.

ExomeDNA results are not intended to be used to start, stop, or change any medication, or to determine a dose. That is a clinical decision.

Related traits and genes

Alcohol use disorder risk shares genetic architecture with several related traits in the ExomeDNA database. Alcohol-related disorders (TRAIT_070872) is the broader phenotypic category that includes hazardous use, alcohol-related liver disease, and social complications of drinking alongside the physical dependence component; the two pages share ADH1B, DRD2, FTO, GCKR, KLB, and SLC39A8, but this page's focus on physical dependence and withdrawal adds the TMPRSS5 ototoxicity angle. Alcohol consumption (drinks per week) reflects habitual intake levels independent of the disorder label, shaped by overlapping but distinct genetic pathways.

Beyond alcohol, several genes here connect to metabolic risk traits. FTO variants influence body mass index and obesity risk independently of alcohol behavior. GCKR variants are associated with type 2 diabetes risk and fasting triglycerides through the same hepatic glucose sensing mechanisms relevant to AUD metabolic complications. DRD2 connects to nicotine dependence and opioid use disorder risk through shared dopamine reward circuitry — a reason why polysubstance use and co-occurring addictions are common.

The ADH1B gene page covers alcohol dehydrogenase enzyme variants in greater depth, including the population-level distribution of the protective rs1229984 allele and its relationship to flush response phenotypes.

Frequently asked questions

References: Verma A et al. (2024). Diversity and scale: Genetic architecture of 2,068 traits in the VA Million Veteran Program. PMID 39024449.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.

Additional research: alcohol dependence (DSM-IV definition)

The genetics behind alcohol dependence risk

The biology of alcohol dependence has two master switches: how fast your body converts alcohol to acetaldehyde, and how fast it clears acetaldehyde away.

The ADH gene cluster (chromosome 4q)

The alcohol dehydrogenase family — ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, and ADH7 — encodes the enzymes responsible for the first step of alcohol metabolism: converting ethanol into acetaldehyde. These seven genes sit in a tight cluster on chromosome 4q and together represent the complete enzymatic machinery for first-pass alcohol oxidation in the liver.

The most consequential variant in this cluster is in ADH1B. The ADH1B2 allele (rs1229984, encoding a histidine-to-arginine substitution at position 47) produces an enzyme that operates 30–40 times faster than the common ADH1B1 form. Carriers of ADH1B*2 oxidize ethanol to acetaldehyde much more rapidly than non-carriers. This matters because acetaldehyde — before it can be cleared — causes flushing, nausea, rapid heartbeat, and a generally unpleasant experience. Genome-wide association studies consistently find ADH1B among the strongest signals for alcohol dependence susceptibility [Treutlein J et al., 2009, PMID 19581569; Park BL et al., 2013, PMID 23456092].

ADH1C contributes additional variation. The ADH1C1 allele (encoding arginine at position 271) catalyzes ethanol oxidation faster than ADH1C2, cooperating with ADH1B to further shape the speed of acetaldehyde production. ADH1A, ADH4, ADH5, ADH6, and ADH7 each have distinct tissue expression profiles and substrate affinities; together they reflect the full breadth of how the human body handles ingested alcohol across different tissues and alcohol concentrations.

ALDH2: the clearance bottleneck

ALDH2, the mitochondrial aldehyde dehydrogenase, handles the second step: converting acetaldehyde to acetate. The ALDH22 variant (rs671, encoding a glutamate-to-lysine substitution at position 487) reduces enzyme activity by more than 90%. Carriers of ALDH22 cannot efficiently clear the acetaldehyde generated by ADH enzymes. Even small amounts of alcohol produce a rapid and intense accumulation of acetaldehyde — causing severe flushing, nausea, headache, and palpitations. This "Asian flush response" (ALDH2*2 is present in approximately 35–40% of East Asian populations) is powerfully protective against developing alcohol dependence, because each drinking experience is physiologically aversive.

The complete pathway

Ethanol (consumed) → ADH1A / ADH1B / ADH1C / ADH4 / ADH5 / ADH6 / ADH7 (fast or slow conversion) → Acetaldehyde → ALDH2 (fast or slow clearance) → Acetate (excreted)

Individuals with fast ADH enzymes (ADH1B2) combined with slow ALDH2 clearance (ALDH22) experience maximum acetaldehyde accumulation — the strongest physiological deterrent to heavy drinking, and the strongest genetic protection against alcohol dependence. The converse — slow ADH, fast ALDH2, efficient clearance — removes this deterrent and is associated with higher population-level dependence risk.

What the research says

Research base: Robust.

The genetics of alcohol dependence is among the most replicated findings in psychiatric and behavioral GWAS. Key findings include:

Treutlein et al. (2009) [PMID 19581569] conducted one of the first genome-wide association studies of alcohol dependence, identifying variants in the ADH gene cluster as top hits, establishing the chromosome 4q locus as a major susceptibility region.

Frank et al. (2012) [PMID 22004471] identified a genome-wide significant association between alcohol dependence and a variant on chromosome 2, demonstrating that susceptibility extends beyond the ADH-ALDH2 axis to neurological pathways — underscoring the polygenic architecture of the trait.

Park et al. (2013) [PMID 23456092] extended genetic analysis of the ADH cluster, describing how the combined effect of multiple ADH variants modulates alcohol dependence risk in a dose-dependent fashion, with ADH1B playing the dominant role.

Gelernter et al. (2014) [PMID 24166409] conducted a large-scale GWAS of alcohol dependence across multiple ancestry groups, identifying significant loci and confirming that ADH1B-region variants are among the most reproducible and largest-effect signals in the literature.

Key statistics from the literature:

• ADH1B*2 carriers show 50–80% lower odds of alcohol dependence in East Asian population studies, one of the largest protective effects documented for any common variant against a complex behavioral trait.
• ALDH2*2 homozygotes have near-zero rates of heavy drinking in most population studies; even heterozygous carriers show substantially reduced alcohol consumption.
• Heritability of alcohol use disorder is estimated at 40–60% from twin studies, indicating that genetic factors explain roughly half of population-level variation in susceptibility.
• Across multiple GWAS, the ADH cluster on chromosome 4q consistently ranks among the top signals, with some individual variants reaching p-values below 10⁻²⁰.

The research is robust: hundreds of independent studies across diverse global populations have confirmed the core ADH-ALDH2 finding. The association between slow ALDH2 clearance and protection from heavy alcohol use is one of the clearest genotype-to-phenotype relationships in behavioral genetics.

Additional research: alcohol-related disorders

The genetics behind alcohol-related disorder risk

Research in this area has identified nine authorized genes relevant to TRAIT_070872. They cluster into three functional groups.

Group 1 — Reward pathway (DRD2, RHOA, ARID4A)

DRD2 encodes the dopamine receptor D2, the primary inhibitory postsynaptic dopamine receptor in the striatum and nucleus accumbens — the core of the brain's mesolimbic reward circuit. When ventral tegmental area (VTA) neurons release dopamine, D2 receptors act as the molecular gate that determines how strongly that dopamine signal is experienced as rewarding.

People with alcohol use disorder have, on average, lower striatal D2 receptor density than matched controls. The mechanism matters: fewer D2 receptors mean that everyday activities — social connection, good food, exercise, creative accomplishment — produce a blunted reward signal. That reward deficit creates a chronic background state of low motivation and dysphoria. Alcohol, by flooding the reward system with dopamine via multiple upstream mechanisms, temporarily resolves that deficit. The pharmacological relief is real, which is precisely what makes the pattern so persistent.

The DRD2 A1 allele (rs1800497, often called the Taq1A variant) is associated with approximately 30–40% lower striatal D2 receptor density. Carriers of the A1 allele are overrepresented among individuals with AUD, and the association replicates across diverse populations.

RHOA encodes RhoA GTPase, a cytoskeletal signaling protein expressed in neurons. In reward circuits, RhoA regulates dendritic spine morphology and synaptic plasticity — the structural remodeling of synapses that underlies long-term learning, including the pathological learning that drives addiction. Repeated alcohol exposure triggers RhoA-mediated synaptic reorganization in the nucleus accumbens, contributing to the neuroadaptations that mark the transition from casual drinking to compulsive use. Variants in RHOA affecting this remodeling capacity may influence how rapidly and durably reward circuits are reshaped by repeated alcohol exposure.

ARID4A is a chromatin remodeling gene involved in epigenetic regulation. Epigenetic mechanisms control gene expression in reward circuits in response to repeated drug exposure. ARID4A variants may alter the epigenetic responsiveness of reward-circuit genes, affecting the depth of neuroadaptation over time.

Group 2 — Hormonal feedback (KLB)

KLB encodes Klotho beta (beta-Klotho), a co-receptor for fibroblast growth factor 21 (FGF21). This is arguably the most novel and scientifically compelling signal in the current gene set.

FGF21 is a hormone produced primarily in the liver. Its release is powerfully induced by alcohol consumption, fructose, and other metabolic stressors. After a bout of drinking, FGF21 levels in the blood rise dramatically within hours. FGF21 then crosses into the brain, where it binds to KLB receptors expressed in the hypothalamus and other regions, and signals: reduce the desire for more alcohol. In rodent experiments, administering FGF21 dose-dependently reduces voluntary alcohol intake. In humans, observational data show that individuals with higher baseline FGF21 levels tend to drink less.

Think of FGF21 as the liver's "enough" signal — a hormonal brake pedal that the brain uses to self-regulate alcohol intake in response to what the liver is experiencing. KLB is the receptor that receives that brake signal.

Genetic variants in KLB that reduce the functional expression or sensitivity of this receptor impair the brain's ability to receive FGF21's stopping signal. Individuals carrying these variants may find that after the first drink or two, the natural hormonal push to stop drinking is weaker, making it easier to continue into a binge pattern. This explains, at a molecular level, a phenomenon many people with AUD describe: once they start, stopping feels actively difficult in a way that is not purely psychological.

This FGF21/KLB axis is an active area of pharmaceutical development. FGF21 analogues are in clinical trials not only for metabolic liver disease but also for alcohol use disorder.

Group 3 — Metabolic signals (ADH1B, ALDH2, FTO, GCKR, SLC39A8)

ADH1B encodes alcohol dehydrogenase 1B, which catalyzes the first step of alcohol metabolism. The fast-metabolizer ADH1B2 variant (common in East Asian and some Middle Eastern populations) accelerates conversion of ethanol to acetaldehyde. The resulting acetaldehyde surge — before ALDH2 can clear it — produces flushing, nausea, and dysphoria that act as a natural deterrent against continued drinking. ADH1B2 carriers have substantially lower rates of AUD. This signal was examined in detail in the companion ADH1B/ALDH2 page (TRAIT_070862); brief mention is included here for completeness.

ALDH2 encodes aldehyde dehydrogenase 2. The ALDH22 loss-of-function variant (highly prevalent in East Asian populations) dramatically slows acetaldehyde clearance, producing the flushing response. Like ADH1B2, ALDH2*2 confers marked protection against AUD through an aversion mechanism. Detailed coverage is available in the companion page.

FTO is best known for its association with body mass index, but it appears in the alcohol-related disorder GWAS reflecting meaningful biological overlap: alcohol is calorie-dense and metabolically disruptive, FTO variants affecting energy sensing and appetite regulation interact with alcohol's effects on energy balance, and the metabolic complications of heavy drinking intersect with FTO's biology in adipose and hypothalamic tissue.

GCKR encodes glucokinase regulatory protein, a key regulator of liver glucose metabolism. The liver is the primary site of alcohol metabolism, and alcohol processing competes with glucose metabolism for the same enzymatic and cofactor resources. GCKR variants that alter hepatic metabolic programming may influence how the liver handles repeated alcohol loads and the downstream metabolic sequelae of heavy drinking.

SLC39A8 encodes a zinc and manganese transporter. Zinc is critical for GABA-A receptor function and antioxidant defense. Chronic heavy alcohol use depletes zinc, impairing GABAergic inhibitory tone and oxidative stress defenses. SLC39A8 variants may modulate both acute alcohol sensitivity and nutritional consequences of prolonged heavy use.

What the research says

Research base: Robust. The genetic architecture of alcohol-related disorders is among the best-characterized in behavioral health genomics. The GWAS underpinning TRAIT_070872 draws on the VA Million Veteran Program (MVP), a biobank that has enrolled over 900,000 U.S. veterans and represents one of the largest and most ancestry-diverse genetic cohorts in the world (Verma A et al., 2024, PMID 39024449). The MVP study analyzed 2,068 clinical traits simultaneously across this diverse sample, providing statistical power and cross-ancestry replication that substantially exceeds earlier single-cohort studies.

The mesolimbic dopamine deficit model — lower D2 receptor density as a trait risk factor — has been replicated in PET imaging studies, genetic association studies, and post-mortem brain tissue analyses. The FGF21/KLB axis evidence comes from both Mendelian randomization studies and pharmacological interventions in model organisms with human confirmatory data.

The picture that emerges is one of multiple partially-independent biological pathways. Metabolic variants (ADH1B, ALDH2) act at the first pharmacological encounter with alcohol. Reward-pathway variants (DRD2) affect baseline reward sensitivity. Hormonal feedback variants (KLB) alter the body's self-regulation after drinking begins. Neuroadaptation variants (RHOA, ARID4A) affect how rapidly the brain structurally reorganizes around repeated alcohol exposure.